This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gentil, V. Articles by Gorenstein, C. Search for Related Content PubMed Articles by Gentil, V. Articles by Gorenstein, C. Social Bookmarking                         What's this?

Clomipramine, a better reference drug for panic/agoraphobia. I. Effectiveness comparison with imipramine

LIM-23 Departamento de Psiquiatria, Faculdade de Medicina

Francisco Lotufo-Neto

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP

Laura Andrade

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP

Táki Cordás

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP

Márcio Bernik

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP

Renato Ramos

Instituto de Psiquiatria, Hospital das Clínicas/FMUSP

Lucia Maciel

LIM-23 Departamento de Psiquiatria, Faculdade de Medicina

Ernesto Miyakawa

LIM-23 Departamento de Psiquiatria, Faculdade de Medicina

Clarice Gorenstein

Departamento de Farmacologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil

An 8-week, double-blind, flexible-dose trial comparing low doses of clomipramine (mean=50 mg) with moderate doses of imipramine (mean=113.8 mg and propanteline (active placebo), was carried out in 60 out-patients with panic disorder with or without agoraphobia. Efficacy evaluation included global, anxiety and depression rating scales, and the determination of rates of relapse over up to 10 weeks of single-blind placebo follow-up. Both tricyclics were significantly more effective than propanteline, but clomipramine tended to act faster and more consistently than imipramine on most measures. Given the degree of blindness achieved and the significantly lower doses of clomipramine, this seems a better reference drug than imipramine for clinical trials in panic/agoraphobia.

Key Words: clomipramine • imipramine • panic disorder

Journal of Psychopharmacology, Vol. 7, No. 4, 316-324 (1993)
DOI: 10.1177/026988119300700402


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. C. de Carvalho, T. Marcourakis, R. Artes, and C. Gorenstein Memory performance in panic disorder patients after chronic use of clomipramine J Psychopharmacol, May 1, 2002; 16(3): 220 - 226. [Abstract] [PDF]

				F. Lotufo-Neto, M. Bernik, R. T. Ramos, L. Andrade, C. Gorenstein, T. Cordas, M. Melo, and V. Gentil A dose-finding and discontinuation study of clomipramine in panic disorder J Psychopharmacol, January 1, 2001; 15(1): 13 - 17. [Abstract] [PDF]

				V. Gentil, F. Kerr-Correa, R. Moreno, E. D. Busnello, J. A. de Campos, M. F. Juruena, B. Lafer, D. H. Moreno, L. d. C. R. Rosa, A. Tiosso, et al. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia J Psychopharmacol, January 1, 2000; 14(1): 61 - 66. [Abstract] [PDF]

				T. Marcourakis, C. Gorenstein, R. T. Ramos, and J. da Motta Singer Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder J Psychopharmacol, January 1, 1999; 13(1): 40 - 44. [Abstract] [PDF]